bipolar disorder

(redirected from Bipolar mania)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
The most commonly reported adverse reactions (incidence[greater than or equal to] 5% and at least twice the rate of placebo) in bipolar mania were extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness and in schizophrenia were extrapyramidal symptoms and akathisia.
For non-response in bipolar mania, consider combining 2 mood stabilisers (e.
adults in placebo-controlled, short-term schizophrenia and bipolar mania trials
Risperidone was approved in August 2007 for the short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder in children and adolescents agede 13-17 years.
The uptake of Latuda, the launch of Forest Laboratories/Gedeon Richter/ Mitsubishi Tanabe Pharma's cariprazine for bipolar mania and the off-label use of newly launchedor emerging atypical antipsychotics, such as Otsuka Pharmaceutical/Lundbeck's brexpiprazole, will only partially offset the decline in sales lost to generic competition within the BPD market.
A 3-week, randomised, placebo controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
The Food and Drug Administration has approved risperidone for the treatment of schizophrenia in adolescents aged 13-17 years and for the short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder in children and adolescents aged 10-17 years, after years of off-label use by many physicians.
The recommended dose for treating adult bipolar mania with Zeldox capsules
These exciting positive Phase III results in patients with bipolar mania demonstrate the potential of cariprazine as a novel antipsychotic agent," said Marco Taglietti, MD.
Food and Drug Administration (FDA) voted to recommend that ADASUVE(TM) (Staccato loxapine) be approved for use as a single dose in 24 hours when used with the FDA recommended Risk Evaluation and Mitigation Strategy (REMS), for the treatment for agitation in patients with schizophrenia or bipolar mania.
The approved uses of risperidone, include the treatment of schizophrenia in adults and adolescents aged 13-17 years, short-term treatment of bipolar mania in adults and pediatric patients aged 10 and older, as well as the treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years.
A 46 week evaluation of aripiprazole in combination with lithium/valproate in bipolar mania.
63 (30 mg/day)] Drug What the Experts Say** lithium Remains one of the first-line drugs recommended by the carbonate American Psychiatric Association (APA) for bipolar mania [Eskalith] and depression; also used for long-term mood maintenance.